This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Dividendos de Akouos

Dividendo controles de criterios 0/6

Información clave

n/a

Rentabilidad por dividendo

n/a

Ratio de pago

Rentabilidad media de la industria	2.8%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Beneficios por acción	-US$2.51
Rentabilidad por dividendo prevista a 3 años	0%

Últimas actualizaciones de dividendos

No hay actualizaciones

Recent updates

Here's Why We're Not Too Worried About Akouos' (NASDAQ:AKUS) Cash Burn Situation

Jun 26

Akouos names Kathy Reape as chief development officer

May 07

We Think Akouos (NASDAQ:AKUS) Can Afford To Drive Business Growth

Mar 04

Did Akouos, Inc. (NASDAQ:AKUS) Insiders Buy Up More Shares?

Jan 10

Akouos (NASDAQ:AKUS) Is In A Good Position To Deliver On Growth Plans

Nov 18

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: Insufficient data to determine if AKUS's dividends per share have been stable in the past.

Dividendo creciente: Insufficient data to determine if AKUS's dividend payments have been increasing.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Akouos vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de AKUS con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (AKUS)	n/a
Suelo de mercado 25% (US)	1.5%
Techo de mercado 25% (US)	4.6%
Media de la industria (Biotechs)	2.8%
Previsión de analistas en 3 años (AKUS)	0%

Dividendo destacado: Unable to evaluate AKUS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Alto dividendo: Unable to evaluate AKUS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Pago de beneficios a los accionistas

Cobertura de los beneficios: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: Unable to calculate sustainability of dividends as AKUS has not reported any payouts.

This company listing is no longer active

Dividendos de Akouos

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos

Recent updates

Akouos, Inc.(NasdaqGS:AKUS) dropped from NASDAQ Composite Index

Akouos, Inc. Announces Executive and Board Changes

Akouos, Inc.(NasdaqGS:AKUS) dropped from NASDAQ Biotechnology Index

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Akouos, Inc. (NasdaqGS:AKUS) from 5AM Venture Management, LLC, New Enterprise Associates, Inc. and others for approximately $460 million.

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Akouos, Inc. (NasdaqGS:AKUS) from 5AM Venture Management, LLC, New Enterprise Associates, Inc. and others.

Is Akouos (NASDAQ:AKUS) In A Good Position To Deliver On Growth Plans?

Akouos, Inc. Receives FDA Clearance of Its IND Application for AK-OTOF, A Gene Therapy Intended for the Treatment of OTOF-Mediated Hearing Loss

Akouos stock rises 11% on FDA nod to start gene therapy trial for hearing loss

Akouos, Inc. Announces Resignation of Chris Smith as Member of the Board of Directors, Effective August 15, 2022

Akouos, Inc.(NasdaqGS:AKUS) dropped from Russell 2500 Index

We Think Akouos (NASDAQ:AKUS) Needs To Drive Business Growth Carefully

Akouos, Inc. Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear At the American Society of Gene and Cell Therapy 25Th Annual Meeting

Price target decreased to US$23.50

We Think Akouos (NASDAQ:AKUS) Can Afford To Drive Business Growth

Companies Like Akouos (NASDAQ:AKUS) Are In A Position To Invest In Growth

Akouos, Inc.(NasdaqGS:AKUS) dropped from Russell 2500 Growth Index

Here's Why We're Not Too Worried About Akouos' (NASDAQ:AKUS) Cash Burn Situation

Akouos, Inc. Presents Nonclinical Data Supporting Future Clinical Development of Ak-Otof and Ak-Antivegf At the American Society of Gene and Cell Therapy 24Th Annual Meeting

Akouos names Kathy Reape as chief development officer

We Think Akouos (NASDAQ:AKUS) Can Afford To Drive Business Growth

New 90-day low: US$17.45

Akouos and Blueprint Genetics Announce the Resonate Program to Improve Access to Genetic Testing for Individuals with Auditory Neuropathy

Did Akouos, Inc. (NASDAQ:AKUS) Insiders Buy Up More Shares?

Akouos (NASDAQ:AKUS) Is In A Good Position To Deliver On Growth Plans

New 90-day low: US$17.99

Akouos, Inc. Appoints Sachiyo Minegishi as Chief Financial Officer

Estabilidad y crecimiento de los pagos

Rentabilidad por dividendo vs. Mercado

Pago de beneficios a los accionistas

Pago en efectivo a los accionistas

Discover strong dividend paying companies